Why Express Scripts Looks Healthy Long-Term
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmacy benefit manager Express Scripts has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Express Scripts and see what CAPS investors are saying about the stock right now.
Express Scriptsfacts
Headquarters (founded) | St. Louis (1986) |
Market Cap | $46.9 billion |
Industry | Healthcare services |
Trailing-12-Month Revenue | $93.9 billion |
Management | Chairman/CEO George Paz CFO Jeffrey Hall |
Return on Equity (average, past 3 years) | 28.7% |
Cash/Debt | $2.8 billion / $15.9 billion |
Competitors | Aetna |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the844 members who have rated Express Scripts believe the stock will outperform the S&P 500 going forward.
Late last month, one of those bulls, All-Star NovaTodd, succinctly summed up the bull case for our community:
Accounting for the recent Medco acquisition, Express Scripts now does business with ~95% of retail pharmacies in the U.S., and possesses significant bargaining power in this relationship (see the Walgreen fiasco for evidence of this). They also have about 60% market share in the mail-order prescriptions business, fertile ground for future growth. Favorable demographic shifts, the closing of the "Medicare donut hole" and a recent share repurchase authorization are just a few more reasons this company is a long term winner.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong five-star rating, Express Scripts may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Express Scripts Looks Healthy Long-Term originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
